By Drug Target Review –
Cincinnati Children’s have made a significant achievement in organoid medicine, with their new study detailing how lab-grown human tissue successfully repaired damaged intestines in a rodent model. This moves decades of research efforts closer to first-in-human clinical trials and could result in novel therapies for conditions such as Crohn’s disease (CD) and ulcerative colitis (UC).
In 2019, Holly Poling, Institutional Investigator at the Center for Stem Cell and Organoid Medicine (CuSTOM) at Cincinnati Children’s, observed microscopic proof that organoids derived from human tissue returned function to a small loop of severely damaged rodent intestine.
